Welcome to our dedicated page for Ge Healthcare Technologies SEC filings (Ticker: GEHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GE HealthCare Technologies Inc. filings document formal disclosures for a medical technology and diagnostics company, including Form 8-K reports on results of operations and financial condition, material agreements, capital-structure matters, and governance changes. Recent current reports include earnings releases, a senior unsecured revolving credit facility, and board-related disclosures.
The company’s proxy materials describe annual-meeting matters, director elections, board committee assignments, executive compensation, equity awards, and shareholder voting procedures. GEHC filings also provide formal context for segment performance, liquidity arrangements, credit covenants, and governance matters tied to its healthcare technology, software, and pharmaceutical diagnostics businesses.
GE HealthCare Technologies Inc. furnished an 8-K to announce that it issued a press release with its fourth quarter 2025 and full-year 2025 financial results. The press release, dated February 4, 2026, is included as Exhibit 99 and is provided under Item 2.02, Results of Operations and Financial Condition.
The company notes that the information in Item 2.02, including Exhibit 99, is furnished rather than filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings. The 8-K also lists Exhibit 104, the cover page formatted in Inline XBRL, and is signed by the Controller and Chief Accounting Officer.
GE HealthCare Technologies Inc. CEO, PDx Kevin Michael O'Neill reported a tax-related share withholding on common stock. On February 1, 2026, 462 shares of GE HealthCare common stock were withheld at a price of $78.97 per share to cover tax obligations associated with vesting restricted stock units.
After this transaction, O'Neill beneficially owned 22,518 shares of common stock directly. He also had an additional 59 shares reported as indirectly owned through a share incentive plan trust. The filing reflects an administrative tax withholding event rather than an open-market purchase or sale.
GE HealthCare Technologies Inc. insider filing: CEO, AVS Philip Rackliffe reported an automatic withholding of 189 shares of common stock on February 1, 2026 at $78.97 per share to cover tax obligations from vesting restricted stock units. After this tax withholding, he beneficially owns 15,393 shares of GE HealthCare common stock directly.
GE HealthCare Technologies Inc. Chief Technology Officer Taha Kass-Hout reported a routine tax-related share withholding. On February 1, 2026, 847 shares of common stock were withheld at $78.97 per share to cover tax obligations tied to vesting restricted stock units.
After this transaction, Kass-Hout beneficially owns 64,103 shares of GE HealthCare common stock in direct ownership. This filing reflects an administrative tax settlement rather than an open-market purchase or sale.
GE HealthCare Technologies Inc. Chief Accounting Officer George A. Newcomb reported a tax-related share withholding. On 02/01/2026, 108 shares of common stock at $78.97 per share were withheld to cover tax obligations tied to vesting restricted stock units.
After this transaction, Newcomb beneficially owned 7,597 shares directly and 12 shares indirectly through a family member.
GE HealthCare Technologies Inc. officer Roland Rott, CEO of Imaging, reported a routine tax-related share withholding. On February 1, 2026, 558 shares of common stock were withheld at $78.97 per share to cover tax obligations from vesting restricted stock units. After this transaction, Rott directly owned 28,564 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc. GC & Corporate Secretary Frank R. Jimenez reported an automatic share withholding related to equity compensation. On February 1, 2026, 947 shares of common stock were withheld at $78.97 per share to cover tax obligations on vested restricted stock units. After this transaction, he directly beneficially owned 67,546 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc.’s Chief Financial Officer, James Saccaro, reported a routine tax‑related share withholding. On February 1, 2026, 948 shares of common stock were withheld at $78.97 per share to cover tax obligations from vesting restricted stock units. After this transaction, Saccaro beneficially owned 57,646 shares of GE HealthCare Technologies common stock, held directly.
GE HealthCare Technologies Inc. President and CEO Peter J. Arduini had 3,210 shares of common stock withheld on February 1, 2026 to cover taxes on vesting restricted stock units. The shares were valued at $78.97 each for this tax withholding event.
After this transaction, Arduini directly beneficially owned 164,672 shares of GE HealthCare Technologies Inc. common stock. This was a tax-related share withholding by the company rather than an open-market sale.
GE HealthCare Technologies Inc. arranged new debt financing to support its acquisition of Intelerad Medical Systems. The company entered into a three-year senior unsecured term loan credit facility that provides a committed $750 million term loan, to be drawn in a single borrowing on a later date once customary conditions are met and repaid in full on the third anniversary of funding. Interest can be based on either an alternate base rate or term SOFR for selected interest periods, with a margin tied to the company’s senior unsecured long-term debt ratings.
The credit agreement includes customary covenants limiting liens, certain fundamental transactions, leverage levels, and subsidiary indebtedness, along with standard events of default such as missed payments, covenant breaches, cross-acceleration of other material debt, bankruptcy events, material judgments, and change of control. Separately, GE HealthCare issued $600 million of 4.150% senior notes due December 15, 2028 and $650 million of 4.950% senior notes due December 15, 2035 under an effective shelf registration. The company plans to use the net proceeds from these notes, together with the term loan and cash on hand, to pay the purchase price of the Intelerad acquisition.